Clinical trials: Alopecia Areata
Alopecia, Chemotherapy Effects
A 6-month Post-interventional Follow-up Extension of VOLUME Study (VOLUME-2)
We would suggest to conduct "VOLUME-2" study, as an extension of the ongoing "VOLUME" study with all subjects already included. After completion of VOLUME study, the study will be directly extend with an "open-label design".
- Trial name
- VOLUME2 (NCT02986412)
- Testing
- CG428
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Samsung Medical Center
Alopecia Areata, Alopecia Totalis
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
Alopecia Areata (AA) is among the most highly prevalent human autoimmune diseases, leading to disfiguring hair loss due to the collapse of immune privilege of the hair follicle and subsequent autoimmune attack.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT06747611
- Testing
- Vancomycin, Neomycin and MTT capsules
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Minnesota
Hair Loss
TCI999 in the Efficacy Verification Program of Hair and Body Health Care
To assess TCI999 on hair and body health care
- Trial name
- NCT05077553
- Testing
- TCI999 probiotic sachet
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Alopecia Areata
Quantification of the Socio-economic Multifacet Burden of Alopecia Areata and Identification of the Associated Factors
Alopecia areata (AA) is a complex autoimmune disorder with an estimated lifetime risk of 1.7% where both genetic pre-disposition and environmental factors contribute.
- Trial name
- PelBurd (NCT05588310)
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Toulouse
Chemotherapy Adjuvant, Breast Cancer
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
The efficacy and safety of the Dignicap System to prevent chemotherapy induced alopecia will be evaluated in women with early breast cancer undergoing adjuvant or neoadjuvant chemotherapy regimens.
- Trial name
- NCT01831024
- Testing
- Dignicap System
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- Target Health Inc.
Alopecia Areata
Plaquenil for Alopecia Areata, Alopecia Totalis
Alopecia areata is an autoimmune condition resulting in hair loss and complete baldness (alopecia totalis). Published evidence says that it is mediated by T-lymphocytes.
- Trial name
- NCT00176982
- Testing
- Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hordinsky, Maria K., MD
Androgenetic Alopecia
A Study to Evaluate the Efficacy and Safety of AD-208
The purpose of this study is to evaluate the efficacy and safety of AD-208.
- Trial name
- NCT04825561
- Testing
- AD-208, AD-2081
- Where
- South Korea
- Volunteers
- 139 people
- Sponsor
- Addpharma Inc.
Hair Loss
Exosomes for Hairloss Treatment
Many people suffer from alopecia, which is caused by hereditary factors, emotional stress, and psychiatric disorders. There are devastating physical and psychological consequences as a result.
- Trial name
- NCT06932393
- Testing
- exosomes, saline
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Androgenetic Alopecia
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
- Trial name
- NCT06916793
- Testing
- CKD-843 dose#1, CKD-843 dose#2, Dutasteride Capsules
- Where
- South Korea
- Volunteers
- 288 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Androgenic Alopecia, Hair Loss/Baldness
Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia
The goal of this study is to determine if Xtresse' gummy is safe and may help regrow hair in men with androgenic alopecia (common pattern hair loss).
- Conditions
- Androgenic Alopecia, Hair Loss/Baldness, Hair Thinning
- Trial name
- NCT07637071
- Testing
- Xtressé Hair Growth Gummies
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Alopecia
Hair Loss Prevention Study for Pancreatic Cancer
Pilot study intended for hair loss prevention in patients with pancreatic cancer who are receiving treatment containing nab-paclitaxel, gemcitabine and cisplatin.
- Trial name
- NCT04492800
- Testing
- Paxman Scalp Cooling Device
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- HonorHealth Research Institute
Androgenetic Alopecia
Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration
The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following…
- Trial name
- NCT04984707
- Testing
- KX0826
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Breast Cancer, Breast - Female
CARE (Chemotherapy Alopecia REduction)
The goal of this research study is to determine if the DigniCap Scalp Cooling System can help prevent chemotherapy-induced hair loss in Black patients.
- Conditions
- Breast Cancer, Breast - Female, Breast Cancer Stage I, Breast Cancer Stage II
- Trial name
- CARE (NCT07201389)
- Testing
- Scalp Cooling by DigniCap
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- George Washington University
Alopecia
Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women
The primary objective of this proposal is to conduct a study that assesses the safety, feasibility and efficacy of using PRP to treat this type of hair loss.
- Trial name
- NCT03488108
- Testing
- Platelet Rich Plasma, Minoxidil Foam
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Alopecia Areata, Fecal Microbiota Transplantation (FMT)
The Role of Gut and Skin Microbiota in Alopecia Areata
The goal of this clinical trial is to learn if fecal microbiota transplantation (FMT) works to treat alopecia areata in adults. It will also learn about the safety of FMT.
- Conditions
- Alopecia Areata, Fecal Microbiota Transplantation (FMT), T Cell Subsets, Microbiome
- Trial name
- RGSM-AA-ICS (NCT07705217)
- Testing
- Fecal Microbial Transplant Enema
- Where
- Croatia
- Volunteers
- 30 people
- Sponsor
- Polyclinic GrandMed
Alopecia Areata
Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata
Alopecia areata is an autoimmune disease associated with infiltration of cluster of differentiation 4(CD4 +) and cluster of differentiation 8 (CD8) + cells around the hair follicles.
- Trial name
- IL2 (NCT01840046)
- Testing
- Interleukin-2
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Androgenetic Alopecia
Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
The purpose of this study is to evaluate the safety and efficacy of three doses of topical NEOSH101 applied once-daily (qd) for 16 weeks in men with thinning hair in the top and center of the scalp (Norwood/Hamilton grades III-IV…
- Trial name
- NCT00471510
- Testing
- tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Neosil, Inc.
Hair Loss
Natural History and Pathogenesis of Alopecia in Children and Adults
Background: Alopecia is the loss of hair or lack of hair growth. It is often related to an immune disorder that disrupts the growth of hair. Hair loss can affect a person s physical and mental health.
- Trial name
- NCT05502796
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Alopecia Areata
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
The purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at Week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.
- Trial name
- NCT05556265
- Testing
- Deucravacitinib
- Where
- 28 sites in United States, Australia and 4 more
- Volunteers
- 94 people
- Sponsor
- Bristol-Myers Squibb
Alopecia Areata
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
This study will use US electronic health records (EHR) linked to US healthcare claims data to describe the baseline demographic and clinical characteristics of AA patients prescribed ritlecitinib; assess its real-world…
- Trial name
- NCT07821216
- Testing
- ritlecitinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer